Teyi Pharmaceutical Group Co.,Ltd
002728.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.26B
Close$
$2.99
68.9% downside
Current Fair Value
68.9% downsideOvervalued by 68.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.26 Billion |
|---|---|
| Enterprise Value | $5.34 Billion |
| Dividend Yield | $0.15 (1.46%) |
| Earnings per Share | $0.16 |
| Beta | 1.37 |
| Outstanding Shares | 502,146,812 |
Return
| Return on Equity | 4.20% |
|---|---|
| Return on Assets | 3.05% |
| Return on Invested Capital | 4.30% |
Valuation & Multiples
| P/E Ratio | 71.86 |
|---|---|
| PEG | -422.43 |
| Price to Sales | 9.63 |
| Price to Book Ratio | 3.21 |
| Enterprise Value to Revenue | 6.46 |
| Enterprise Value to EBIT | 68.4 |
| Enterprise Value to Net Income | 71 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.26 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 20, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$80.00 M
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$80.00 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Teyi Pharmaceutical Group Co.,Ltd
1,621 employees
CEO: Danqing Xu Teyi Pharmaceutical Group Co., Ltd. is a Chinese pharmaceutical company that focuses on the development, production, and sale of a broad range of medicinal products within China. Its offerings include both proprietary traditional Chinese...